This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Actgen Inc. Active years: 2014.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2014
Title: Emi Shimizu: Innovator in Anti-Cancer Antibody Development
Introduction
Emi Shimizu is a prominent inventor based in Komagane, Japan. She has made significant contributions to the field of cancer research through her innovative work on antibodies with anti-cancer activity. Her dedication to advancing medical science is evident in her research and patent achievements.
Latest Patents
Emi Shimizu holds a patent for an antibody having anti-cancer activity. By utilizing an SST-REX method, she selected a cDNA encoding a protein expressed on a cell surface or secreted from a cancer cell line from a cDNA library derived from a cancer cell line. Monoclonal antibodies against the protein encoding the selected cDNA were prepared. The in vitro and in vivo anti-cancer activities and binding to various cancer cell lines were examined. As a result, a monoclonal antibody that binds to a PODXL2 protein, which had excellent anti-cancer activities, was found. Furthermore, a region including an epitope of the antibody was successfully identified, and the amino acid sequences of variable regions of a light chain and a heavy chain were successfully determined. This patent represents a significant advancement in cancer treatment options.
Career Highlights
Emi Shimizu's career is marked by her innovative research and development in the field of biotechnology. Her work has not only contributed to scientific knowledge but also holds the potential for practical applications in cancer therapy. She is associated with Actgen Inc., where she continues to pursue her research interests.
Collaborations
Emi has collaborated with notable colleagues, including Masunori Kajikawa and Masahito Sugiura. These collaborations have further enriched her research and contributed to the success of her projects.
Conclusion
Emi Shimizu is a trailblazer in the development of anti-cancer antibodies, with a patent that showcases her innovative approach to cancer treatment. Her work exemplifies the impact of dedicated research in the fight against cancer.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile